Edition:
United Kingdom

Seattle Genetics Inc (SGEN.OQ)

SGEN.OQ on NASDAQ Stock Exchange Global Select Market

54.16USD
20 Feb 2018
Change (% chg)

$-0.32 (-0.59%)
Prev Close
$54.48
Open
$54.00
Day's High
$55.48
Day's Low
$54.00
Volume
230,375
Avg. Vol
406,836
52-wk High
$71.31
52-wk Low
$45.31

Select another date:

Wed, Feb 14 2018

BRIEF-Pharma Mar Licenses Marine-Derived Payloads To Seattle Genetics

* LICENSES FULLY SYNTHETIC MARINE-DERIVED PAYLOADS TO SEATTLE GENETICS FOR USE IN DRUG CONJUGATES

BRIEF-Seattle Genetics And Pieris Pharmaceuticals Announce Multi-Program Immuno-Oncology Collaboration

* SEATTLE GENETICS AND PIERIS PHARMACEUTICALS ANNOUNCE MULTI-PROGRAM IMMUNO-ONCOLOGY COLLABORATION

BRIEF-Pieris Pharmaceuticals And Seattle Genetics Announce Multi-Program Immuno-Oncology Collaboration

* PIERIS PHARMACEUTICALS AND SEATTLE GENETICS ANNOUNCE MULTI-PROGRAM IMMUNO-ONCOLOGY COLLABORATION Source text for Eikon: Further company coverage:

BRIEF-Seattle Genetics Commences Tender Offer For Cascadian Therapeutics

* SEATTLE GENETICS COMMENCES TENDER OFFER FOR CASCADIAN THERAPEUTICS, INC.

BRIEF-Seattle Genetics Announces Full Exercise Of Underwriters’ Option To Purchase Additional Shares

* SEATTLE GENETICS ANNOUNCES FULL EXERCISE OF UNDERWRITERS’ OPTION TO PURCHASE ADDITIONAL SHARES Source text for Eikon: Further company coverage:

BRIEF-Seattle Genetics Says If Deal Terminated Under, Cascadian Therapeutics To Pay Fee Of $17 Million

* SEATTLE GENETICS SAYS IF DEAL TERMINATED UNDER CERTAIN CIRCUMSTANCES, CASCADIAN THERAPEUTICS MAY BE REQUIRED TO PAY CO FEE OF $17 MILLION - SEC FILING Source text: (http://bit.ly/2E2RNXK) Further company coverage:

BRIEF-Seattle Genetics Commences Underwritten Public Offering Of $550 Mln Of Shares

* SEATTLE GENETICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

BRIEF-Seattle Genetics To Acquire Cascadian Therapeutics

* SEATTLE GENETICS TO ACQUIRE CASCADIAN THERAPEUTICS, ADDING LATE-STAGE BREAST CANCER PROGRAM TO ITS ONCOLOGY PIPELINE

BRIEF-SEATTLE GENETICS ANNOUNCES FDA APPROVAL OF ADCETRIS (BRENTUXIMAB VEDOTIN)

* SEATTLE GENETICS ANNOUNCES FDA APPROVAL OF ADCETRIS® (BRENTUXIMAB VEDOTIN) FOR PRIMARY CUTANEOUS ANAPLASTIC LARGE CELL LYMPHOMA (PCALCL) AND CD30-EXPRESSING MYCOSIS FUNGOIDES (MF)

BRIEF-Seattle Genetics, Astellas initiate phase 1b trial for Enfortumab Vedotin

* Seattle Genetics and Astellas initiate phase 1B trial of Enfortumab Vedotin in combination with immune checkpoint inhibitor therapies in locally advanced or metastatic urothelial cancer

Select another date: